Mutations in rpoB gene and genotypes of rifampin resistant Mycobacterium tuberculosis isolates in Iran

Tanaffos

Volumn 7, Issue 2, 2008, Pages 11-17

  Doustdar, Farahnoosh ^a,b   Khosravi, Azar Dokht ^a   Farnia, Parissa ^b   Bahrmand, Ahmad Reza ^c   Masjedi, Mohammad Reza ^b   Velayati, Ali Akbar ^b  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Mycobacterium tuberculosis; Rifampin resistance; RpoB gene; Spoligotyping

Indexed keywords

DNA; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CODON; DNA EXTRACTION; DNA FINGERPRINTING; DNA SEQUENCE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENOTYPE; HUMAN; IRAN; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 70350436989     PISSN: 17350344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282 (7): 677-86.
2. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328 (8): 527-32.
3. Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 1988; 202 (1): 45-58.
4. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344 (17): 1294-303.
5. Espinal MA. The global situation of MDR-TB. Tuberculosis (Edinb) 2003; 83 (1-3): 44-51.
6. Chaisson RE. Treatment of chronic infections with rifamycins: Is resistance likely to follow? Antimicrob Agents Chemother 2003; 47 (10): 3037-9.
7. Heep M, Brandstätter B, Rieger U, Lehn N, Richter E, Rüsch-Gerdes S, et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001; 39 (1): 107-10.
8. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 2006; 12 (5): 736-43.
9. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin Microbiol 1997; 35 (4): 907-14.
10. Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Locht C. Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol Microbiol 2000; 36 (3): 762-71.
11. Fan XY, Hu ZY, Xu FH, Yan ZQ, Guo SQ, Li ZM. Rapid detection of rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis isolates in shanghai by using the amplification refractory mutation system. J. Clin Microbiol 2003; 41 (3): 993-7.
12. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341 (8846): 647-50. 13 Kent PT, Kubica GP. Public Health Mycobacteriology, a Guide for the Level III Laboratory. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention. 1985.
13. Inderlied CB, Nash KA. Antimycobacterial agents: In vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids, In Antibiotics in Laboratory Medicine, 4th ed, Edited by V. Lorain. Baltimore: Williams & Wilkins; 1996. pp. 127-75.
14. van Soolingen D, de Haas PE, Hermans PW, van Embden JD. DNA fingerprinting of Mycobacterium tuberculosis. Methods Enzymol 1994; 235: 196-205.
15. Nikolayevsky V, Brown T, Balabanova Y, Ruddy M, Fedorin I, Drobniewski F. Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J Clin Microbiol 2004; 42 (10): 4498-502.
16. Van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: Main methodologies and achievements. J Intern Med 2001; 249 (1): 1-26.
17. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: Recommendations for a standardized methodology. J Clin Microbiol 1993; 31 (2): 406-9.
18. Filliol I, Driscoll JR, van Soolingen D, Kreiswirth BN, Kremer K, Valétudie G, et al. Snapshot of moving and expanding clones of Mycobacterium tuberculosis and their global distribution assessed by spoligotyping in an international study. J Clin Microbiol 2003; 41 (5): 1963-70.
19. Bártfai Z, Somoskövi A, Ködmön C, Szabó N, Puskás E, Kosztolányi L, et al. Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J Clin Microbiol 2001; 39 (10): 3736-9.
20. Tracevska T, Jansone I, Broka L, Marga O, Baumanis V. Mutations in the rpoB and katG genes leading to drug resistance in Mycobacterium tuberculosis in Latvia. J Clin Microbiol 2002; 40 (10): 3789-92.
21. Van Der Zanden AG, Te Koppele-Vije EM, Vijaya Bhanu N, Van Soolingen D, Schouls LM. Use of DNA extracts from Ziehl-Neelsen-stained slides for molecular detection of rifampin resistance and spoligotyping of Mycobacterium tuberculosis. J Clin Microbiol 2003; 41 (3): 1101-8.
22. Mani C, Selvakumar N, Narayanan S, Narayanan PR. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol 2001; 39 (8): 2987-90.
23. Velayati AA, Farnia P, Mirsaeidi M, Reza Masjedi M. The most prevalent Mycobacterium tuberculosis superfamilies among Iranian and Afghan TB cases. Scand J Infect Dis 2006; 38 (6-7): 463-8.
24. Suresh N, Singh UB, Arora J, Pant H, Seth P, Sola C, et al. rpoB gene sequencing and spoligotyping of multidrug resistant Mycobacterium tuberculosis isolates from India. Infect Genet Evol 2006; 6 (6): 474-83.
25. Krüüner A, Hoffher SE, Sillastu H, Danilovits M, Levina K, Tanaffos 2008; 7(2): 11-16
26. Svenson SB, et al. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001; 39 (9): 3339-45.
27. Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA. Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol 2002; 40 (6): 1930-7.
28. Farnia P, Masjedi MR, Mirsaeidi M, Mohammadi F, Jallaledin-Ghanavi, Vincent V, et al. Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients. J Infect 2006; 53 (5): 331-6.
29. Qian L, Abe C, Lin TP, Yu MC, Cho SN, Wang S, et al. rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J Clin Microbiol 2002; 40 (3): 1091-4.
30. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43 (8): 1866-9.